Susceptibility to bone damage
AssigneeBodysync, Inc.
InventorsAndreas Gerardus Uitterlinden, Joyce Berdina Josepha van Meurs
Life of this patent
Estimating the term…
Abstract
In one aspect, the present invention provides methods for determining susceptibility to bone damage in a subject. In some embodiments, the methods comprise screening for polymorphisms in the MTHFR and collagen Iα1 genes that are associated with susceptibility to bone damage. In some embodiments, the methods comprise screening for elevated levels of homocysteine in a subject, wherein elevated levels of homocysteine are associated with an increased risk of bone damage. The methods of the invention may be used in predicting the response of a patient to treatment. Also provided are methods for prevention or reducing the risk of bone damage in a subject.
Claims21
1-32. (canceled)
A method of determining susceptibility of a subject to bone damage, said method comprising:
- obtaining a sample from said subject;
- and
- detecting a level of homocysteine in said sample, wherein a presence of an elevated level of homocysteine in said sample compared to a level of homocysteine in a reference population is indicative of an increase susceptibility of said subject to bone damage.
A method of determining susceptibility of a subject to bone damage, said method comprising:
- obtaining a sample from said subject;
- and
- detecting a level of homocysteine in said sample, wherein if said level of homocysteine in said sample is greater than 20 μmol/l, said subject has an increased susceptibility of bone damage.
Dependencies are inferred from the claim text.